Suppr超能文献

开发和验证一种风险评分,以预测非肝硬化肝脏中肝细胞癌手术后的总生存。

Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Queen Elizabeth Hospital, Birmingham, B15 2WB, United Kingdom.

Department of Hepatobiliary and Pancreatic Surgery, Queen Elizabeth Hospital, Birmingham, B15 2WB, United Kingdom.

出版信息

HPB (Oxford). 2020 Mar;22(3):383-390. doi: 10.1016/j.hpb.2019.07.007. Epub 2019 Aug 12.

Abstract

BACKGROUND

The aim of this study was to develop and validate a risk score to predict overall survival (OS) in patients undergoing surgical resection for hepatocellular carcinoma in non-cirrhotic liver (NC-HCC).

METHODS

Patients who underwent resection for NC-HCC between 2004 and 2013 were identified from the SEER database. A derivation set of 75% of this cohort was used to develop a risk score. This was then internally validated on the remaining patients, and externally validated using a cohort of patients from The HPB Unit, Birmingham, UK.

RESULTS

A total of 3897 patients were included from the SEER database, with a median post-diagnosis survival of 59 months. In the derivation set, multivariable analyses identified male sex, increasing tumour size, the presence of multiple tumours, bilobar tumours and major vascular invasion as adverse prognostic factors. A risk score generated from these factors was significantly predictive of OS, and was used to classify patients into low, medium and high-risk groups. These groups had a five-year OS of 69%, 51% and 19% in the internal, and 73%, 50% and 45% in the external validation sets.

CONCLUSION

The proposed risk score is useful in the selection, pre-operative consenting and counselling of patients for surgery and to allow patients to make an informed decision regarding treatment.

摘要

背景

本研究旨在开发并验证一个预测非肝硬化肝癌(NC-HCC)患者接受手术切除后总生存期(OS)的风险评分。

方法

从 SEER 数据库中确定了 2004 年至 2013 年期间接受 NC-HCC 切除术的患者。该队列的 75%用于开发风险评分。然后在其余患者中进行内部验证,并使用来自英国伯明翰 HPB 单位的患者队列进行外部验证。

结果

从 SEER 数据库中纳入了 3897 例患者,中位诊断后生存时间为 59 个月。在推导组中,多变量分析确定男性、肿瘤大小增加、多个肿瘤、双侧肿瘤和大血管侵犯是不良预后因素。从这些因素生成的风险评分可显著预测 OS,并用于将患者分为低、中、高危组。这些组在内部验证集和外部验证集中的五年 OS 分别为 69%、51%和 19%,73%、50%和 45%。

结论

所提出的风险评分可用于选择、术前同意和咨询患者手术,并允许患者就治疗做出明智的决定。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验